Ceftazidime-avibactam (Avycaz): For the treatment of complicated intra-abdominal and urinary tract infections

P and T

Volumn 41, Issue 8, 2016, Pages 479-483

  Mosley, Juan F ^a   Smith, Lillian L ^a   Parke, Crystal K ^a   Brown, Jamal A ^a   Wilson, Alton L ^a   Gibbs, Lydia V ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; MEROPENEM; METRONIDAZOLE; PROBENECID;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANXIETY DISORDER; CANDIDIASIS; CONSTIPATION; CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DYSGEUSIA; EOSINOPHILIA; HEADACHE; HEART ELECTROPHYSIOLOGY; HUMAN; HYPOKALEMIA; INJECTION SITE PHLEBITIS; MACULOPAPULAR RASH; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NAUSEA; NOTE; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN BINDING; PRURITUS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA; URINARY TRACT INFECTION; URTICARIA; VOMITING;

EID: 84988409073     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (14)

1. Levi J, Segal LM, Lieberman DA, et al. Outbreaks: protecting Americans from infectious disease. Trust for America’s Health. December 2014. Available at: http://healthyamericans.org/assets/files/TFAH-2014-OutbreaksRpt-FnlRv.pdf. Accessed July 23, 2015.
2. van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis 2013;75;(2):115–120.
3. H.R. 2182. Generating Antibiotic Incentives Now Act of 2011, 12th Cong 2011–2012. June 16, 2011. Available at: www.congress.gov/bill/112th-congress/house-bill/2182. Accessed July 7, 2016.
4. Food and Drug Administration. Novel new drugs 2014 summary. January 2015;Available at: www.fda.gov/downloads/drugs/developmentapprovalprocess/druginnovation/ucm430299.pdf. Accessed June 30, 2016.
5. Food and Drug Administration. FDA approves new antibacterial drug Avycaz [news release]. February262015;Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435629.htm. Accessed July 7, 2015.
6. Adult UTI. American Urological Association. Available at: www.auanet.org/education/adult-uti.cfm. Accessed July 16, 2015.
7. National Institute for Health and Care Excellence. Complicated intra-abdominal infections: ceftolozane/tazobactam June 2016;Available at: www.nice.org.uk/advice/esnm75/chapter/Key-points-from-the-evidence. Accessed July 7, 2016.
8. Avycaz (ceftazidime/avibactam) prescribing information Cincinnati, Ohio: Forest Pharmaceuticals, Inc.. 2016;Available at: www.allergan.com/assets/pdf/avycaz_pi. Accessed June 30, 2016.
9. Zerbaxa (ceftolozane-tazobactam) prescribing information Whitehouse Station, New Jersey: Merck. 2015;Available at: www.merck.com/product/usa/pi_circulars/z/zerbaxa/zerbaxa_pi.pdf. Accessed July 6, 2016.
10. Mahoney MV. Superheroes of gram-negative bacteria. Pharmacy Times March 62015;Available at: www.pharmacytimes.com/contributor/monica-v-golik-mahoney-pharmd-bcps-aq-id/2015/03/superheroes-of-gram-negative-bacteria. Accessed July 8, 2015.
11. Red Book Online. Avycaz Ann Arbor, Michigan: Truven Health Analytics. Accessed July 6, 2016.
12. Red Book Online. Metronidazole Ann Arbor, Michigan: Truven Health Analytics. Accessed July 7, 2016.
13. Taneja N, Kaur H. Insights into newer antimicrobial agents against gram-negative bacteria. Microbiol Insights 2016;9:9–19.
14. Red Book Online. Zerbaxa Ann Arbor, Michigan: Truven Health Analytics. Accessed July 7, 2016.